Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TENACITY: Tenecteplase in Acute Ischemic Stroke >4.5h
NCT07361302Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2026
- Primary completion
- Oct 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 16
01
Overview
A Phase 3 trial of tenecteplase in ischemic stroke, sponsored by Boehringer Ingelheim. Started Feb 2026; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07361302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361302.